BALAXI — Balaxi Pharmaceuticals Cashflow Statement
0.000.00%
- IN₹2.03bn
- IN₹2.21bn
- IN₹2.93bn
Annual cashflow statement for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 443 | 545 | 569 | 20.2 | 287 |
| Depreciation | |||||
| Non-Cash Items | -8.82 | 6.78 | 62.8 | -32.4 | 55.3 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -437 | -216 | -589 | 39.9 | -711 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.032 | 341 | 60.8 | 48.7 | -350 |
| Capital Expenditures | -12.8 | -53.2 | -131 | -6.93 | -211 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -47 | -231 | 24.9 | -3.54 | -6.45 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -59.7 | -284 | -106 | -10.5 | -218 |
| Financing Cash Flow Items | -0.131 | -1.42 | -3.54 | -14.8 | -26.9 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 36.5 | -1.63 | 255 | 303 | 339 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -23.2 | 55.3 | 210 | 341 | -229 |